MATTHEW BREYER, MD
Osteopathic Medicine in Nashville, TN
License number
Tennessee MD16845
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
3601 Tvc, Nashville, TN 37232
Phone
(615) 322-3000
Personal information
See more information about MATTHEW BREYER at radaris.comName
Address
Phone
6 Warwick Ln, Nashville, TN 37205
Organization information
See more information about MATTHEW BREYER at bizstanding.comMatthew Breyer MD
3601 Tvc, Nashville, TN 37232
Industry:
Internist
Phone:
(615) 322-3000 (Phone)
Matthew Douglas Breyer
Professional information
See more information about MATTHEW BREYER at trustoria.com
Dr. Matthew Breyer - MD (Doctor of Medicine)
Dr. Matthew Breyer - MD (Doctor of Medicine)
Hospitals:
3601 Tvc, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
3601 Tvc, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
3601 Tvc, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
Education:
Medical Schools
Harvard Medical School
Graduated: 1979
Harvard Medical School
Graduated: 1979
Selective Inhibition Of Cyclooxygenase 1 In The Treatment Of Diabetic Nephropathy
Selective Inhibition Of Cyclooxygenase 1 In The Treatment Of Diabetic Nephropathy
US Patent:
2005014, Jun 30, 2005
Filed:
Dec 8, 2004
Appl. No.:
11/007060
Inventors:
Matthew Breyer - Nashville TN, US
International Classification:
A61K031/60, A61K031/401, A61K031/192, A61K031/05
US Classification:
514165000, 514569000, 514570000, 514423000, 514733000
Abstract:
The present invention relates to the use of COX-1 selective inhibitors to treat diabetic nephropathy. In particular, COX-1 inhibitors may be combined with standard insulin replacment therapy, and/or combined with ACE inhbitor therapy. The therapy is, in a specific embodiment, designed to inhibit systemic COX-1 activity, reflected by inhibition of platelet-stimulated thromboxane production, while not inhibiting macrophage PGE2 production.
Cox2 Inhibition In The Prevention And Treatment Of Autosomal Dominant Polycystic Kidney Disease
Cox2 Inhibition In The Prevention And Treatment Of Autosomal Dominant Polycystic Kidney Disease
US Patent:
2004002, Feb 5, 2004
Filed:
Apr 2, 2003
Appl. No.:
10/405959
Inventors:
Matthew Breyer - Nashville TN, US
Assignee:
Vanderbilt University
International Classification:
A61K031/415, A61K031/365
US Classification:
514/406000, 514/473000
Abstract:
The present invention provides a new therapeutic approach for autosomal dominant polycystic kidney disease (ADPKD). Cyclooxygenase 2 (COX2) inhibitors are used, alone or in combination with other drugs, to prevent or limit early stage cyst formation.